Edition:
India

Aerie Pharmaceuticals Inc (AERI.OQ)

AERI.OQ on NASDAQ Stock Exchange Global Market

11.94USD
1:30am IST
Change (% chg)

$0.29 (+2.49%)
Prev Close
$11.65
Open
$11.80
Day's High
$11.97
Day's Low
$11.59
Volume
235,380
Avg. Vol
317,366
52-wk High
$26.23
52-wk Low
$10.81

Latest Key Developments (Source: Significant Developments)

Aerie Pharmaceuticals Submits Prior Approval Supplement To The U.S. FDA To Allow Production Of Rocklatan 0.02%/0.005% In Its Athlone Ireland Facility
Thursday, 19 Sep 2019 

Sept 19 (Reuters) - Aerie Pharmaceuticals Inc ::AERIE PHARMACEUTICALS SUBMITS PRIOR APPROVAL SUPPLEMENT TO THE U.S. FOOD AND DRUG ADMINISTRATION TO ALLOW PRODUCTION OF ROCKLATAN® (NETARSUDIL AND LATANOPROST OPHTHALMIC SOLUTION) 0.02%/0.005% IN ITS ATHLONE IRELAND FACILITY.AERIE PHARMACEUTICALS SUBMITS PRIOR APPROVAL SUPPLEMENT TO THE U.S. FOOD AND DRUG ADMINISTRATION TO ALLOW PRODUCTION OF ROCKLATAN® (NETARSUDIL AND LATANOPROST OPHTHALMIC SOLUTION) 0.02%/0.005% IN ITS ATHLONE IRELAND FACILITY.AERIE PHARMACEUTICALS INC - BASED ON FDA TIMELINES, AERIE EXPECTS PAS FILING REVIEW TO BE COMPLETED WITHIN 60 DAYS, WITH FINAL PAS REVIEW IN 4 MONTHS.AERIE PHARMACEUTICALS INC - COMPANY ANTICIPATES PREAPPROVAL INSPECTION OF ATHLONE MANUFACTURING PLANT DURING 4-MONTH REVIEW.AERIE PHARMACEUTICALS- PLANS TO FILE A PAS IN H1 2020 TO OBTAIN FDA APPROVAL TO MANUFACTURE RHOPRESSA 0.02% IN ATHLONE.  Full Article

Aerie Pharmaceuticals Initiates Clinical Trial Of AR-13503 Sustained Release Intravitreal Implant In Patients With Neovascular Macular Degeneration And Diabetic Macular Edema
Tuesday, 20 Aug 2019 

Aug 20 (Reuters) - Aerie Pharmaceuticals Inc ::AERIE PHARMACEUTICALS INITIATES FIRST-IN-HUMAN CLINICAL TRIAL OF AR-13503 SUSTAINED RELEASE INTRAVITREAL IMPLANT IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION AND DIABETIC MACULAR EDEMA.AERIE PHARMACEUTICALS INC - STUDY WILL EVALUATE SAFETY AND PRELIMINARY EFFICACY OF AR-13503 SR IMPLANT AS MONOTHERAPY AND WITH AFLIBERCEPT.  Full Article

Aerie Pharmaceuticals Q2 Adjusted Loss Per Share $0.80
Thursday, 8 Aug 2019 

Aug 7 (Reuters) - Aerie Pharmaceuticals Inc ::AERIE PHARMACEUTICALS REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS, UPDATES FULL-YEAR 2019 GUIDANCE AND PROVIDES BUSINESS UPDATE.Q2 ADJUSTED LOSS PER SHARE $0.80.Q2 GAAP LOSS PER SHARE $1.04.Q2 EARNINGS PER SHARE ESTIMATE $-0.86 -- REFINITIV IBES DATA.AERIE PHARMACEUTICALS - BASED ON U.S. LAUNCH TRAJECTORY EXPERIENCE YEAR-TO-DATE IN 2019, FY 2019 NET REVENUE GUIDANCE ADJUSTED TO RANGE OF $70 MILLION TO $80 MILLION.NET CASH BURN GUIDANCE FOR FULL-YEAR 2019 IS NOW AT $160 MILLION TO $170 MILLION.AS OF JUNE 30, 2019, AERIE HAD CASH AND CASH EQUIVALENTS OF $109.4 MILLION.QTRLY TOTAL REVENUES, NET $15.8 MILLION VERSUS $2.4 MILLION.  Full Article

Aerie Pharmaceuticals Announces FDA Approval Of Rocklatan
Wednesday, 13 Mar 2019 

March 12 (Reuters) - Aerie Pharmaceuticals Inc ::AERIE PHARMACEUTICALS ANNOUNCES U.S. FDA APPROVAL OF ROCKLATAN(NETARSUDIL AND LATANOPROST OPHTHALMIC SOLUTION) 0.02%/0.005% FOR THE REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION.AERIE PHARMACEUTICALS INC - COMPANY PLANS TO LAUNCH ROCKLATAN IN UNITED STATES IN Q2 OF 2019.  Full Article

Aerie Pharma Q4 GAAP Loss Per Share $1.14
Tuesday, 26 Feb 2019 

Feb 25 (Reuters) - Aerie Pharmaceuticals Inc ::AERIE PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS, PROVIDES 2019 CASH BURN GUIDANCE AND BUSINESS UPDATE.Q4 ADJUSTED LOSS PER SHARE $0.92.Q4 GAAP LOSS PER SHARE $1.14.Q4 EARNINGS PER SHARE ESTIMATE $-0.87 -- REFINITIV IBES DATA.AERIE PHARMACEUTICALS - GUIDANCE FOR 2019 FULL-YEAR CASH BURN IS CONSISTENT WITH FULL-YEAR 2018 ACTUAL RESULTS, IN RANGE OF $210 MILLION TO $220 MILLION.ENTERING 2019 VERY WELL FINANCED, WITH OVER $300 MILLION IN AVAILABLE LIQUIDITY.Q4 REVENUE $14.5 MILLION.  Full Article

Aerie Pharmaceuticals Files Supplement Related To Offering Of 329,124 Shares By Selling Stockholders - SEC Filing
Thursday, 23 Aug 2018 

Aug 22 (Reuters) - Aerie Pharmaceuticals Inc ::AERIE PHARMACEUTICALS INC FILES PROSPECTUS SUPPLEMENT RELATES TO OFFERING OF 329,124 SHARES OF CO'S COMMON STOCK BY SELLING STOCKHOLDERS - SEC FILING.  Full Article

BRIEF-Aerie Pharmaceuticals Says Board Approved Increase In Size Of Board To Nine Members From Eight

* AERIE PHARMACEUTICALS INC - ON JUNE 9, BOARD APPROVED AN INCREASE IN SIZE OF BOARD FROM EIGHT MEMBERS TO NINE MEMBERS Source text: (https://bit.ly/37hZ2Yi) Further company coverage: